

Letters

RESEARCH LETTER


Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

The SARS-CoV-2 messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have each shown more than 90% efficacy in preventing COVID-19 illness^{1,2} but, to our knowledge, humoral immune responses have not been compared directly.

Methods | Health care workers at a tertiary care center (Ziekenhuis Oost-Limburg, Belgium) who were scheduled for vaccination

with 2 doses of either mRNA-1273 or BNT162b2 were invited to participate in this prospective cohort. Serologic testing was performed prior to vaccination as well as 6 to 10 weeks after the second dose (between April 27 and May 20, 2021). Total immunoglobulin levels to the receptor-binding domain of the SARS-CoV-2 spike protein were measured with an anti-SARS-CoV-2 S enzyme immunoassay (Elecsys, Roche Diagnostics International Ltd). After vaccination, antibodies against the SARS-CoV-2 nucleocapsid protein were determined. Previous infection was defined as anti-nucleocapsid positivity at any point, anti-spike positivity before vaccination, and/or a history of positive polymerase chain reaction results on nasopharyngeal swab.

Figure. Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination



Violin plots of circulating SARS-CoV-2 anti-spike protein receptor-binding domain antibodies in serum samples obtained from participants after they received 2 doses of an mRNA vaccine. Inside each violin plot, the geometric mean is depicted as a point. A, Difference between participants vaccinated with mRNA-1273 (Moderna) vs those with BNT162b2 (Pfizer-BioNTech).

B, Difference according to previous SARS-CoV-2 infection and the type of mRNA vaccine. C, Difference according to age and the type of mRNA vaccine in previously uninfected participants. All comparisons were significant at $P < .001$ except previously infected participants (panel B), which was significant at $P = .01$.

Table. Multivariable Linear Regression Model of log₁₀-Transformed Antibody Levels After Second Dose of an mRNA COVID-19 Vaccine

	Regression coefficient (95% CI)	P value
Vaccine type		
BNT162b2	[Reference]	
mRNA-1273	0.359 (0.326 to 0.392)	<.001
Previous infection with SARS-CoV-2		
Uninfected	[Reference]	
Infected	0.692 (0.649 to 0.736)	<.001
Age, per year (starting at 21 y)	-0.006 (-0.007 to -0.004)	<.001
Sex		
Male	[Reference]	
Female	0.047 (0.005 to 0.089)	.03
Time between vaccination and testing, per day	-0.005 (-0.006 to -0.003)	<.001

Antibody levels were compared after the second dose of each vaccine for the entire cohort; for those previously infected vs uninfected; and by age group (<35, 35-55, and >55 years) among previously uninfected individuals, using the *t* test after log₁₀ transformation. Correlation between age and log₁₀-transformed antibody levels was assessed with Pearson correlation. To adjust for confounding, a multiple linear regression was fitted with inclusion of age, sex, previous infection, and time between vaccination and serologic testing. All tests were 2-sided with statistical significance set at $\alpha = .05$. Analyses were performed using RStudio (version 1.2.1335). This study was approved by the local institutional review board; participants provided written informed consent.

Results | Of 2499 health care workers who received 2 doses of SARS-CoV-2 mRNA vaccines, 1647 participated in this study. A total of 688 were vaccinated with mRNA-1273 (mean age, 43.2 years; 76.7% women; 21.8% previously infected with SARS-CoV-2), and 959 with BNT162b2 (mean age, 44.7 years; 84.9% women; 13.2% previously infected).

Higher antibody titers were observed in participants vaccinated with 2 doses of mRNA-1273 compared with those vaccinated with BNT162b2 (geometric mean titer [GMT], 3836 U/mL [95% CI, 3586-4104] vs 1444 U/mL [95% CI, 1350-1544]; $P < .001$) (Figure, A).

Previously infected participants had higher antibody titers (GMT, 9461 U/mL [95% CI, 8494-10 539]) compared with previously uninfected participants (GMT, 1613 U/mL [95% CI, 1539-1690]) ($P < .001$). In both groups, those vaccinated with mRNA-1273 had higher antibody titers compared with those vaccinated with BNT162b2 (previously uninfected: GMT, 2881 U/mL [95% CI, 2721-3051] vs 1108 U/mL [95% CI, 1049-1170]; $P < .001$; previously infected: GMT, 10 708 U/mL [95% CI, 9311-12 315] vs 8174 U/mL [95% CI, 6923-9649]; $P = .01$). The difference in antibody levels according to previous infection was higher than the difference between the 2 mRNA vaccines (Figure, B and Table).

Antibody levels negatively correlated with age in previously uninfected participants (correlation coefficient, -0.22 ; $P < .001$), being highest among those younger than 35 years. Across all age categories, previously uninfected participants

vaccinated with mRNA-1273 had higher antibody titers compared with those vaccinated with BNT162b2 ($P < .001$ for all comparisons; Figure, C).

The type of mRNA vaccine remained independently associated with the log-transformed antibody titer in a multiple linear regression ($P < .001$, Table).

Discussion | This study demonstrated a significantly higher humoral immunogenicity of the SARS-CoV-2 mRNA-1273 vaccine (Moderna) compared with the BNT162b2 vaccine (Pfizer-BioNTech), in infected as well as uninfected participants, and across age categories. The higher mRNA content in mRNA-1273 compared with BNT162b2 and the longer interval between priming and boosting for mRNA-1273³ (4 weeks vs 3 weeks for BNT162b2) might explain this difference.

A relationship between neutralization level after SARS-CoV-2 vaccination and protection against COVID-19 has been demonstrated by several studies.⁴ As such, the height of the humoral response after vaccination, which correlates with neutralizing antibody titers,⁵ might be clinically relevant.

Limitations of this study include the lack of data on cellular immunity and on neutralizing antibodies, as well as the specific focus on health care workers. Whether the observed difference in antibody level translates to a difference in the duration of protection,⁴ the protection against variants of concern, and the risk of transmission⁶ needs further investigation. Future research should also address the relevance for patients with reduced antibody response after vaccination.

Deborah Steensels, PharmD, PhD

Noella Pierlet, MSc

Joris Penders, MD, PhD

Dieter Mesotten, MD, PhD

Line Heylen, MD, PhD

Author Affiliations: Ziekenhuis Oost-Limburg, Genk, Belgium.

Corresponding Author: Deborah Steensels, PharmD, PhD, Department of Laboratory Medicine, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600 Genk, Belgium (Deborah.steensels@zol.be).

Accepted for Publication: August 19, 2021.

Published Online: August 30, 2021. doi:10.1001/jama.2021.15125

Author Contributions: Drs Steensels and Heylen had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Steensels, Penders, Mesotten, Heylen.

Acquisition, analysis, or interpretation of data: Steensels, Pierlet, Penders, Heylen.

Drafting of the manuscript: Steensels, Heylen.

Critical revision of the manuscript for important intellectual content: Pierlet, Penders, Mesotten, Heylen.

Statistical analysis: Steensels, Pierlet, Heylen.

Obtained funding: Steensels, Penders, Mesotten.

Administrative, technical, or material support: Steensels, Penders, Mesotten.

Supervision: Steensels, Penders.

Conflict of Interest Disclosures: None reported.

Funding/Support: Roche Diagnostics International Ltd provided test reagents and Interreg Euregio Meuse-Rhine provided financial support (grant EMR-187 CODAP).

Role of the Funder/Sponsor: Funders were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Additional Contributions: We thank Maarten Coemans, MSc, PhD (Leuven Biostatistics Centre, KU Leuven), for his statistical advice. He was not compensated for his contribution.

1. Baden LR, El Sahly HM, Essink B, et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
2. Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
3. Voysey M, Costa Clemens SA, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet*. 2021;397(10277):881-891. doi:10.1016/S0140-6736(21)00432-3
4. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*. 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
5. Rubio-Acero R, Castelletti N, Fingerle V, et al; KoCo19 study team. In search of the SARS-CoV-2 protection correlate: head-to-head comparison of two quantitative S1 assays in pre-characterized oligo-/asymptomatic patients. *Infect Dis Ther*. 2021;10(3):1505-1518. doi:10.1007/s40121-021-00475-x
6. Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. *Nat Med*. 2021;27(5):790-792. doi:10.1038/s41591-021-01316-7